Minnetronix Medical's division Minnetronix Neuro has co-founded The Neurapheresis Consortium with Duke University to accelerate development of therapies for underserved diseases involving the central nervous system.
Image: Minnetronix Neuro launches Neurapheresis Consortium. Photo: Courtesy of yodiyim/FreeDigitalPhotos.net.
Designed to bring together leading researchers and clinicians, the consortium will accelerate the advancement of Neurapheresis Therapy, intended to improve outcomes for multiple, underserved patient populations, suffering from diseases involving infectious, inflammatory and neurodegenerative agents in the central nervous system.
Working in partnership with disease experts across the globe, Nandan Lad, M.D., Associate Professor of Neurosurgery at Duke, will lead the consortium’s efforts to advance Neurapheresis Therapy through pre-clinical research, and ultimately into the clinic for multiple indications.
Neurapheresis Therapy is built on a proprietary technology platform developed by Minnetronix Neuro that is designed to prevent secondary injury and enhance healing by removing disease causing agents from the cerebral spinal fluid.
Lad said: “We are building an exceptional team of global disease and medical technology experts to advance our research and develop truly novel therapies.
“The Neurapheresis Consortium will unite the world’s leading authorities on specific disease states, medical technology experts and organizations that support grant-based funding, to help us deliver meaningful solutions to patients suffering from debilitating and life-threatening neurological conditions.”
Minnetronix Neuro will bring significant product development expertise to the consortium. The company began building its portfolio following the acquisition of patented technology that it developed into the Neurapheresis Therapy. Aaron McCabe Ph.D., head of research and development for Minnetronix Neuro, will provide nearly twenty years of medtech industry experience to the consortium.
Minnetronix Neuro general manager Matt Adams said: “Our goal is simple: To improve outcomes for neuro patients who currently have few, if any, treatment options.
“The Neurapheresis Consortium represents a powerful force of knowledge, skill and determination that will help transform the very real needs of patients suffering from neurological disease into life-enhancing solutions.”
Source: Company Press Release.